Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo

British Journal of Pharmacology

Volumn 173, Issue 4, 2016, Pages 729-740

  Sampson, Amanda K ^a   Irvine, Jennifer C ^a   Shihata, Waled A ^a   Dragoljevic, Dragana ^a   Lumsden, Natalie ^a   Huet, Olivier ^a   Barnes, Tyrone ^a,b   Unger, Thomas ^c   Steckelings, Ulrike M ^d   Jennings, Garry L ^a   Widdop, Robert E ^b   Chin Dusting, Jaye P F ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; COMPOUND 21; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LIPID DIET; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULITIS; AGONISTS; ANIMAL; CELL ADHESION; CELL CULTURE; CHEMISTRY; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOLIPOPROTEINS E; CELL ADHESION; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LEUKOCYTES; MALE; MICE; MICE, KNOCKOUT; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 2; SIGNAL TRANSDUCTION; SULFONAMIDES; THIOPHENES;

EID: 84957442777     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13063     Document Type: Article

References (32)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Barber MN, Sampey DB, Widdop RE, (1999). At(2) receptor stimulation enhances antihypertensive effect of at(1) receptor antagonist in hypertensive rats. Hypertension 34: 1112-1116.
4. Brouwers S, Smolders I, Massie A, Dupont AG, (2013). Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo. Hypertension 62: 920-926.
5. Dandapat A, Hu CP, Chen J, Liu Y, Khan JA, Remeo F, et al. (2008). Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochem Biophys Res Commun 366: 871-877.
6. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA, (2004). Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the at1a receptor. Circulation 110: 3849-3857.
7. Dhande I, Ma W, Hussain T, (2015). Angiotensin at2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated thp-1 macrophages via increased interleukin-10 production. Hypertens Res 38: 21-29.
8. Fu Y, Moore XL, Lee MK, Fernandez-Rojo MA, Parat MO, Parton RG, et al. (2012). Caveolin-1 plays a critical role in the differentiation of monocytes into macrophages. Arterioscler Thromb Vasc Biol 32: e117-e125.
9. Gordon S, Taylor PR, (2005). Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
10. Hilliard LM, Jones ES, Steckelings M, Unger T, Widdop RE, Denton KM, (2012). Sex-specific influence of angiotensin type 2 receptor stimulation on renal function; a novel therapeutic target for hypertension. Hypertension 59: 409-414.
11. Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, et al. (1999). Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 103: 627-635.
12. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM, et al. (2008). Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates lox-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 199: 288-294.
13. Huet O, Laemmel E, Fu Y, Dupic L, Aprico A, Andrews KL, et al. (2013). Interleukin 10 antioxidant effect decreases leukocytes/endothelial interaction induced by tumor necrosis factor alpha. Shock 39: 83-88.
14. Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, et al. (2005). Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein e-null mice. Circulation 112: 1636-1643.
15. Jacobs LS, Douglas JG, (1996). Angiotensin II type 2 receptor subtype mediates phospholipase a2-dependent signaling in rabbit proximal tubular epithelial cells. Hypertension 28: 663-668.
16. Johren O, Dendorfer A, Dominiak P, (2004). Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res 62: 460-467.
17. Li Z, Iwai M, Wu L, Liu HW, Chen R, Jinno T, et al. (2004). Fluvastatin enhances the inhibitory effects of a selective at1 receptor blocker, valsartan, on atherosclerosis. Hypertension 44: 758-763.
18. Lokuta AJ, Cooper C, Gaa ST, Wang HE, Rogers TB, (1994). Angiotensin II stimulates the release of phospholipid-derived second messengers through multiple receptor subtypes in heart cells. J Biol Chem 269: 4832-4838.
19. Matrougui K, Loufrani L, Heymes C, Levy BI, Henrion D, (1999). Activation of at(2) receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries. Hypertension 34 (4 Pt 1): 659-665.
20. McCarthy CA, Vinh A, Callaway JK, Widdop RE, (2009). Angiotensin at2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 40: 1482-1489.
21. Michell DL, Andrews KL, Woollard KJ, Chin-Dusting JP, (2011). Imaging leukocyte adhesion to the vascular endothelium at high intraluminal pressure. J Vis Exp 54: 3221.
22. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
23. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL, (2012). Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59: 291-299.
24. Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, Thone-Reineke C, et al. (2010). Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappab. Hypertension 55: 924-931.
25. Sales VL, Sukhova GK, Lopez-Ilasaca MA, Libby P, Dzau VJ, Pratt RE, (2005). Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 112: 3328-3336.
26. Sampson AK, Moritz KM, Jones ES, Flower RL, Widdop RE, Denton KM, (2008). Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension 52: 666-671.
27. Tesanovic-Kljajic ST, Widdop RE, Vinh A, Welungoda I, Bosnyak S, Jones ES, et al. (2013). Direct at(2) receptor stimulation is athero-protective and stabilizes plaque in apolipoprotein e-deficient mice. Int J Cardiol 169: 281-287.
28. Widdop RE, Matrougui K, Levy BI, Henrion D, (2002). At2 receptor-mediated relaxation is preserved after long-term at1 receptor blockade. Hypertension 40: 516-520.
29. Woollard KJ, Suhartoyo A, Harris EE, Eisenhardt SU, Jackson SP, Peter K, et al. (2008). Pathophysiological levels of soluble p-selectin mediate adhesion of leukocytes to the endothelium through mac-1 activation. Circ Res 103: 1128-1138.
30. Woollard KJ, Lumsden NG, Andrews KL, Aprico A, Harris E, Irvine JC, et al. (2014). Raised soluble p-selectin moderately accelerates atherosclerotic plaque progression. PLoS ONE 9: e97422.
31. Wu L, Iwai M, Li Z, Shiuchi T, Min LJ, Cui T X, et al. (2004). Regulation of inhibitory protein-kappa-b and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol 18: 666-678.
32. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M, (1998). Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci 63: PL289-PL295.